






# Responsum Health

Clinical Trial Recruitment | Case Studies

Helping research move forward  
—one patient at a time.



# Idiopathic Pulmonary Fibrosis Campaign




**Start of services date:** October 2020

**End of services date:** February 2021

**Therapeutic Area:** Idiopathic Pulmonary Fibrosis

**Campaign Basics:** Phase II - Rescue - Rare Disease



## Study Details:

Phase II clinical study for patients with IPF. Responsum was brought in to boost enrollment in the US market quickly. This was the first time Responsum supported a clinical trial campaign.

## Study requirements and goals:

- Campaign has been slow in the US. 20+ randomized patients needed quickly.

## Challenges:

- Beginning of the COVID-19 pandemic.
- Rare disease.
- Older population which represented a challenge for digital outreach.
- 1 year long study.

## Strategy and results:

Leveraging our 3.6K+ member pulmonary fibrosis community, we launched a targeted campaign centered on clinical trial education, streamlined phone screening, and a personalized email drip campaign designed to align with participants' preferences and demographics.

**52 patients were referred successfully, 13 screened, and 8 randomized. All from our IPF community.**

## Final assessment:

*Although the trial ended early due to unforeseen circumstances, Galapagos was highly pleased with the results achieved in a short time. This success inspired us to expand our capabilities to better support clinical trial recruitment for all our community members.*

# Chronic Cough Campaign




**Start of services date:** September, 2022

**End of services date:** February, 2023

**Therapeutic Area:** Chronic Cough

**Campaign Basics:** Phase II - Rescue



## Study Details:

Phase II clinical study for patients with chronic cough. Responsum was brought in to boost enrollment as current strategies were unsuccessful.

## Study requirements and goals:

- Current enrollment: 2/30
- Months remaining: 4
- High patient burden. If enrolled, participants had to wear a 24-hour device, complete a 2-hour post-dose assessment, and go to back-to-back visits.

## Results:

**212 high quality of patients referred in less than 3 months.** 65% of them are part of our Long Covid community and are highly educated on clinical trials.

**52 patients were screened, and 28 patients enrolled from Responsum referrals,** meeting client's expectations.

## Sponsor Review

*“Responsum campaign doubled the recruitment efforts, **nearly cutting the enrollment period in half!** Without the Responsum campaign, we likely would have had to continue recruitment into the following quarter.” — Study Sponsor*

# Retinitis Pigmentosa Campaign




**Start of services date:** August, 2022

**End of services date:** January, 2023

**Therapeutic Area:** Retinitis Pigmentosa

**Campaign Basics:** Phase II - Rare Disease



## Study Details:

Phase II - Single center clinical study for patients with Retinitis Pigmentosa.

## Study requirements and goals:

- Current enrollment: 2/8
- Months remaining: 5
- Very rare eye disease.
- This campaign were looking for participants diagnosed with RP due to a specific gene mutation. Making enrollment even more challenging.

## Strategy and Results:

Leveraging our partnership with a leading non-profit for eye health and digital marketing strategies, we identified and pre-screened hundreds of patients with RP. Our strategy included comprehensive phone screening, multiple follow-ups, and close collaboration with the site.

**53 patients were referred, 16 patients were screened, and 7 enrolled as a result of our efforts.**

## Sponsor Review


*“Responsum raised to the challenge! Thank you for contributing to this important company milestone!” — Study Sponsor*

# Nephrotic Syndrome Campaign



**Start of services date:** February, 2023  
**End of services date:** November, 2023

**Therapeutic Area:** Nephrotic Syndrome  
**Campaign Basics:** Phase II - Rare Disease



## Study Details:

Phase II clinical study for patients with Nephrotic Syndrome including MCD and FSGS.

## Study requirements and goals:

- Rare disease.
- Hard qualification criteria due to diagnosis and medications not allowed.
- 50+ referrals needed in 6 month time frame starting. Hoping to yield 8-10 enrollments from Responsum.

## Strategy and Results:

We utilized our CKD community and partnered with a patient advocacy group in the FSGS and MCD space to identify eligible patients for this study. Due to the study's strict qualification criteria and internal dynamics, an amendment to the protocol was required. Responsum quickly adapted to these changes by updating our portal and study materials to ensure seamless recruitment.

**As a result, 77 patients were referred to clinical sites, leading to 18 successful screenings and 8 enrolled participants.**

## Sponsor Review

*“Responsum’s collaboration with patient communities and advocacy groups allowed us to connect with highly targeted participants. Their dedication and efficiency were instrumental in advancing our trial, and we look forward to future partnerships.” — Study Sponsor*